COMPANY OVERVIEW

Rigontec is the leader in RIG-I targeting therapeutics. Utilizing our proprietary RIG-I agonist platform, we harness one of the most essential pathways in the innate immune system to pioneer a novel immuno-oncology treatment approach.

---

LOCATION

Planegg/Martinsried, , Germany

Cambridge, MA, USA

---

THERAPEUTIC AREAS

Oncology

---

WEBSITE

https://rigontec.com/

---

CAREER WEBSITE

https://rigontec.com/team/jobs/

---

SOCIAL MEDIA

---

INVESTORS

---

---

PRESS RELEASES

Sep 6, 2017

Merck to Acquire Rigontec, RIG-I Therapeutics Pioneer, Advancing Leadership in Immuno-Oncology

May 3, 2017

Rigontec Starts First-In-Human, Phase I/II Trial of RIG-I Agonist RGT100 and Appoints Eugen Leo as Chief Medical Officer

Nov 15, 2016

Rigontec Appoints Dr. Jörg Vollmer as Chief Scientific Officer

Jul 15, 2015

Rigontec GmbH Appoints Donald J. deBethizy as Chairman of the Board

Mar 24, 2015

Rigontec GmbH Raises €4.8m in a Second Closing of its Series A Financing

For More Press Releases

---